Sucampo Pharmaceuticals, Inc. (“Sucampo” or “the Company”) (NASDAQ: SCMP) (SPI) today announced that RESCULA ® (unoprostone isopropyl ophthalmic solution) 0.15% is now available by prescription across the United States. The U.S. Food and Drug Administration (FDA) approved a sNDA for RESCULA for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension on December 7, 2012. “RESCULA is an important prostone-based treatment option for patients suffering from open-angle glaucoma, which is the most common form of glaucoma,” said Sucampo’s Chairman, Chief Executive Officer, and Chief Scientific Officer Ryuji Ueno, M.D., Ph.D., Ph.D. “We have already received positive feedback from many in the ophthalmology and optometry communities regarding RESCULA’s unique mechanism of action as a BK channel activator, and we are pleased that patients will now have access to the drug in order to help treat this disease.” According to the approved product labeling, RESCULA may be used as a first-line agent or concomitantly with other topical ophthalmic drug products to lower intraocular pressure. RESCULA is a BK (Big Potassium) channel activator, which is different from other IOP lowering agents. Company to Host Conference Call February 21 at 5:00 pm In conjunction with this press release, Sucampo will host a conference call on February 21 at 5:00 pm Eastern to give an overview of commercial launch plans for RESCULA. To participate on the live call, please dial 800-798-2884 (domestic) or 617-614-6207 (international), and provide the participant passcode 71967726, five to ten minutes ahead of the start of the call. A replay of the call will be available within a few hours after the call ends. Investors may listen to the replay by dialing 888-286-8010 (domestic) or 617-801-6888 (international), with the passcode 79910549. Investors interested in accessing the live audio webcast of the teleconference may do so at http://investor.sucampo.com and should log on before the teleconference begins in order to download any software required. The archive of the teleconference will remain available for 30 days. About Unoprostone Isopropyl (RESCULA) Unoprostone isopropyl is a member of Sucampo’s family of prostones and is a synthetic docosanoid. Unoprostone isopropyl may have a local effect on BK (Big Potassium) channels in the eye. BK channels are expressed in contractile tissues like the trabecular meshwork. RESCULA may reduce elevated intraocular pressure (IOP) by increasing the outflow of aqueous humor through the trabecular meshwork. Complete details of the mechanism of action are unknown at this time.